Johnson & Johnson (NYSE:JNJ) was the recipient of a large growth in short interest in the month of October. As of October 30th, there was short interest totalling 12,770,000 shares, a growth of 13.9% from the October 15th total of 11,210,000 shares. Based on an average trading volume of 6,420,000 shares, the days-to-cover ratio is presently 2.0 days. Currently, 0.5% of the company’s stock are sold short.
Several brokerages have recently issued reports on JNJ. Cantor Fitzgerald lifted their price target on Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday, October 14th. Raymond James reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Friday. Stifel Nicolaus lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, Credit Suisse Group boosted their price target on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research note on Wednesday, October 14th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $164.93.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the sale, the executive vice president now directly owns 66,658 shares in the company, valued at approximately $10,233,336.16. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.27% of the company’s stock.
Shares of Johnson & Johnson stock traded down $0.78 on Friday, hitting $146.36. The company’s stock had a trading volume of 6,356,142 shares, compared to its average volume of 8,102,407. Johnson & Johnson has a 52-week low of $109.16 and a 52-week high of $157.00. The company has a quick ratio of 1.24, a current ratio of 1.48 and a debt-to-equity ratio of 0.51. The firm has a fifty day moving average price of $145.51 and a 200-day moving average price of $146.57. The company has a market capitalization of $385.30 billion, a P/E ratio of 23.01, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.98 by $0.22. The firm had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The company’s revenue was up 1.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.12 EPS. As a group, analysts expect that Johnson & Johnson will post 7.99 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.01 per share. This represents a $4.04 dividend on an annualized basis and a yield of 2.76%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Story: How Investors Use a Balance Sheet
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.